Bcl-2 Promotes Invasion and Lung Metastasis by Inducing Matrix Metalloproteinase-2
Bcl-2 is involved in the progression of human malignancies, but the precise role and mechanism of Bcl-2 for tumor invasion and metastasis remains unclear. In this study, we have investigated the role and mechanism of Bcl-2 on tumor cell invasion and metastasis by using Bcl-2 overexpressing non–small cell lung cancer cells. Matrix metalloproteinases (MMPs) are important proteins involved in the processes of tumor invasion and metastasis. In vitro Matrigel invasion assays showed that Bcl-2 overexpression increased tumor cell invasion by 15-fold. Moreover, Bcl-2 overexpression enhanced in vivo lung metastasis by 4-fold. Consistent with its effect on invasion and metastasis, Bcl-2 overexpression induced not only MMP-2 mRNA and its protein expression, but this also activated the pro-MMP-2 protein to its active form. To explore the induction mechanism of MMP-2 by Bcl-2, we investigated the effects of Bcl-2 overexpression on MMP-2 transcriptional regulation. Nuclear run-on assays showed a 6-fold increase in the transcription rate of MMP-2 mRNA in the Bcl-2 transfectants (H157/Bcl-2) compared with that of the H157/vector control cells (H157/C). Overexpression of Bcl-2 induced the nuclear transcription factor activator protein 1 family, including the c-Jun, JunD, c-Fos, FosB, and Fra-1 proteins. Reporter assays combined with deletion mutagenesis analysis and gel shift assays showed the involvement of activator protein 1 in the activation of MMP-2 promoter activity by Bcl-2. Taken together, we have shown that Bcl-2 promotes tumor invasion and lung metastasis by inducing MMP-2 gene expression through the combined action of transcriptional and posttranslational mechanisms.
Top-30
Journals
|
1
2
3
|
|
|
Oncotarget
3 publications, 3.33%
|
|
|
Tumor Biology
3 publications, 3.33%
|
|
|
Cancer Research
3 publications, 3.33%
|
|
|
Frontiers in Oncology
2 publications, 2.22%
|
|
|
BMC Cancer
2 publications, 2.22%
|
|
|
British Journal of Cancer
2 publications, 2.22%
|
|
|
Journal of Experimental and Clinical Cancer Research
2 publications, 2.22%
|
|
|
Scientific Reports
2 publications, 2.22%
|
|
|
PLoS ONE
2 publications, 2.22%
|
|
|
Journal of Thoracic Oncology
2 publications, 2.22%
|
|
|
Cellular Signalling
2 publications, 2.22%
|
|
|
Journal of Cellular Biochemistry
2 publications, 2.22%
|
|
|
Carcinogenesis
2 publications, 2.22%
|
|
|
Oncology Letters
2 publications, 2.22%
|
|
|
Current Pharmaceutical Design
1 publication, 1.11%
|
|
|
Aging
1 publication, 1.11%
|
|
|
Anti-Cancer Drugs
1 publication, 1.11%
|
|
|
International Journal of Molecular Sciences
1 publication, 1.11%
|
|
|
Pharmaceutics
1 publication, 1.11%
|
|
|
Medical Oncology
1 publication, 1.11%
|
|
|
Journal of Molecular Medicine
1 publication, 1.11%
|
|
|
Molecular Biology Reports
1 publication, 1.11%
|
|
|
Journal of Translational Medicine
1 publication, 1.11%
|
|
|
Annals of Surgical Oncology
1 publication, 1.11%
|
|
|
Cell Death and Differentiation
1 publication, 1.11%
|
|
|
Bulletin of Experimental Biology and Medicine
1 publication, 1.11%
|
|
|
BMC Systems Biology
1 publication, 1.11%
|
|
|
Cancer Gene Therapy
1 publication, 1.11%
|
|
|
Journal of Pharmaceutical Investigation
1 publication, 1.11%
|
|
|
Cell Death and Disease
1 publication, 1.11%
|
|
|
1
2
3
|
Publishers
|
5
10
15
20
25
|
|
|
Springer Nature
25 publications, 27.78%
|
|
|
Elsevier
22 publications, 24.44%
|
|
|
Wiley
6 publications, 6.67%
|
|
|
American Association for Cancer Research (AACR)
6 publications, 6.67%
|
|
|
Impact Journals
4 publications, 4.44%
|
|
|
SAGE
4 publications, 4.44%
|
|
|
Oxford University Press
3 publications, 3.33%
|
|
|
Spandidos Publications
3 publications, 3.33%
|
|
|
MDPI
2 publications, 2.22%
|
|
|
Frontiers Media S.A.
2 publications, 2.22%
|
|
|
Public Library of Science (PLoS)
2 publications, 2.22%
|
|
|
American Society for Microbiology
2 publications, 2.22%
|
|
|
American Chemical Society (ACS)
2 publications, 2.22%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 1.11%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 1.11%
|
|
|
Taylor & Francis
1 publication, 1.11%
|
|
|
Hindawi Limited
1 publication, 1.11%
|
|
|
American Physiological Society
1 publication, 1.11%
|
|
|
American Society of Clinical Oncology (ASCO)
1 publication, 1.11%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 1.11%
|
|
|
5
10
15
20
25
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.